Market Overview

Teva Receives Positive Opinion from EMA's CHMP to Extend Indication of Trisenox for First Line Treatment of Low- to Intermediate Risk Acute Promyelocytic Leukemia

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK
RECENT PRO ALERTS

Posted-In: News FDA

 

Related Articles (TEVA)